The potential role of renin angiotensin system in acute leukemia: a narrative review

Portes e Silva, Kacio Roger; Nogueira, Eugênia Maia; Jesus Mendes, André Luiz de; Pena, Ana Luisa Batista; Simões e Silva, Ana Cristina

doi:10.1007/s11033-024-09659-3

Mol Biol Rep

2024

DOI: 10.1007/s11033-024-09659-3

|View full text |Cite

The potential role of renin angiotensin system in acute leukemia: a narrative review

Kacio Roger Portes e Silva,

Eugênia Maia Nogueira,

André Luiz de Jesus Mendes

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Arterial Stiffness as a New Predictor of Clinical Outcome in Patients with Polycythemia Vera

Mulas,

Sestu,

Costa

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Thrombotic adverse events and disease progression are crucial in Polycythemia Vera (PV), as it stands as the leading cause of mortality. The pulse wave velocity (PWV) is a valuable indicator of arterial aging and often plays a significant independent role in contributing to cardiovascular adverse events (CV-AEs). The aim of this study was to examine the relationship between PWV and critical vascular function parameters, with the goal of identifying new predictive factors of vascular damage and exploring a potential connection with disease progression. Methods: Non-invasive aortic stiffness was assessed through carotid–femoral PWV measurement. PWV was measured using the SphygmoCor device. History of arterial or venous thrombosis (TAEs) or other CV-AEs was collected at baseline. PWV measurements were repeated at baseline, at 6 and at 12 months. Results: The study involved 28 PV patients aged 27 to 77 years, with 57.1% being male. Fourteen patients (50%) reported a high-risk thrombotic score at diagnosis, and 60.7% had at least one comorbidity. Multivariable regression models showed that hemoglobin levels were independently associated with PWV (β: 0.68, SE 0.24, p < 0.01). During the follow-up period (median duration 21.3 months, range 6–33), a total of 13 events were documented. Specifically, two patients exhibited a loss of response to treatment, four patients presented an increase in spleen diameters, three patients displayed an escalation of systemic symptoms, and three patients had a clear progression to secondary myelofibrosis. PWV (per 1 m/s: OR 1.70, 95% CI 1.00–2.91, p = 0.047) and leukocyte count (per 1 × 103/μL: OR 1.47, 95% CI: 1.04–2.09, p = 0.043) were significant predictors of events, independently of waist circumference, blood pressure, treatment, and hematocrit. Conclusions: PWV has demonstrated its potential as an effective tool for monitoring PV patients. It stands as a clinical parameter that can predict the risk of progression in PV patients. Further investigation is essential to fully explore this potential. If successful, it could offer clinicians a valuable resource for effectively managing PV patients.

show abstract

Arterial Stiffness as a New Predictor of Clinical Outcome in Patients with Polycythemia Vera

Mulas,

Sestu,

Costa

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

Nanotechnology based approaches for leukemia therapy

2024

Biomed. Lett.

View full text Add to dashboard Cite

Leukemia, a leading cause of cancer-related morbidity and mortality, primarily affect blood-forming tissues. It is classified into four main types: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL). These subtypes vary in characteristics and prevalence, affecting different age groups, from children to adults, with prognosis heavily influenced by the type and severity of the disease. Conventional treatments for leukemia, including chemotherapy, radiation, and stem cell therapy, have notable limitations, such as non-specific targeting, high costs, drug resistance, and issues related to donor compatibility. These limitations underscore the urgent need for innovative solutions. One of the major challenges in treating leukemia with tyrosine kinase inhibitors (TKIs) is the frequent resistance due to factors like lack of specific targeting, underdosing, limited bioavailability, and severe adverse effects. Nanotechnology presents a promising solution to these challenges by utilizing nanoscale materials such as liposomes, metallic nanoparticles, polymeric nanoparticles, and biomimetic nanoparticles for targeted drug delivery. Nanoparticle-based drug delivery systems offer enhanced drug targeting, reduced systemic toxicity, and improved therapeutic efficacy. This review highlights recent advancements in nanotechnology to improve leukemia treatment.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The potential role of renin angiotensin system in acute leukemia: a narrative review

Cited by 2 publications

References 50 publications

Arterial Stiffness as a New Predictor of Clinical Outcome in Patients with Polycythemia Vera

Arterial Stiffness as a New Predictor of Clinical Outcome in Patients with Polycythemia Vera

Nanotechnology based approaches for leukemia therapy

Contact Info

Product

Resources

About